Statin adherence improves with age and subsequent treatment sequences: A retrospective cohort study using Proportion of Days Covered (PDC)

Varování

Publikace nespadá pod Ústav výpočetní techniky, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

TICHOPÁD Aleš DONIN Gleb ŽIGMOND Jan RÁFL Jakub RYBÁŘ Marian ŠEDOVÁ Petra VRABLÍK Michal

Rok publikování 2025
Druh Článek v odborném periodiku
Časopis / Zdroj PLOS One
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0325293
Doi https://doi.org/10.1371/journal.pone.0325293
Popis Background Dyslipidaemia is a key risk factor for atherosclerotic cardiovascular disease (ASCVD), necessitating effective statin therapy. Despite statins’ proven safety and efficacy, adherence remains suboptimal, with significant gaps between clinical practice and guideline recommendations. Methods This retrospective cohort study analysed anonymized health administrative claims data from six employee health funds in the Czech Republic, covering approximately 40% of the insured population from January 1, 2017, to December 31, 2020. We identified statin-incident as well as prevalent cohort of patients. Adherence to statin therapy was assessed using the proportion of days covered (PDC) metric, with factors such as age, gender, sequence of use, and treatment intensity considered as modifiers. Results Among the statin-prevalent cohort (SP, n?=?890,180), 83.5% achieved a PDC???50%, and 61.0% reached a PDC???80%. In the statin-incident cohort (SI, n?=?287,871), a clear trend of increasing adherence with age and medication sequence was observed: in adults aged 18–39 median PDC rose from 84.1% (IQR: 57–100) in the first to 94.7% (IQR: 75.6–100) in the third sequence; in those aged 80?+?median PDC rose from 95.0% (IQR: 68.9–100) in the first to 100% (IQR: 78.3–100) in the third sequence. Logistic regression identified age (OR=1.011 per year), female gender (OR=0.896), high-intensity treatment (OR=0.975), and second (OR=1.267) or later treatment sequences (OR=1.704) as significant predictors of adherence (all p?<?0.001). Conclusion Adherence to statin therapy improves with subsequent treatment sequences and age. These findings highlight the need for targeted interventions to enhance adherence, particularly among younger patients. The PDC metric is recommended for integration into clinical practice to monitor and improve medication adherence.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info